Manufacturing Partnerships Quell has partnered with AGC Biologics for CDMO services signaling openness to external manufacturing and tech transfer. Their proprietary toolbox for Treg engineering and multi modular autologous Treg candidates makes them a capable supplier for GMP manufacturing process development and supply chain programs for companies developing immune tolerant therapies in autoimmune diseases and transplantation.

Engineered Treg Focus Quell specializes in engineered Treg cell therapies and has a QEL 005 CAR Treg program aimed at complex autoimmune diseases. This positions them as a strong partner for pharma seeking advanced cell therapy candidates co development or licensing opportunities to leverage Foxp3 phenotype lock and other engineering modules.

Clinical Data Opportunities Quell actively presents data at major conferences such as ACR Convergence ESGCT and AASLD The Liver Meeting, indicating ongoing clinical and translational work in solid organ transplantation and autoimmune conditions. Opportunities exist for joint studies data licensing or sponsored research collaborations to accelerate milestones.

Global Footprint Quell is based in London with a global presence through conference activity enabling partnerships for EU and UK regulatory strategy and cross border manufacturing for international programs.

Growth Readiness With broad funding and a growing team Quell demonstrates readiness for co development milestone based partnerships and capacity expansion in manufacturing and translational science.